Downloads: 1
Diff of
/clusters/3009knumclusters/clust_1.txt
[000000]
..
[c09aa8]
Switch to unified view
| a | b/clusters/3009knumclusters/clust_1.txt | ||
|---|---|---|---|
| 1 | Active infection requiring systemic therapy |
||
| 2 | The subject has or had any active infection requiring systemic antibiotic, antifungal or antiviral therapy within the past 4 weeks |
||
| 3 | Active infection that requires systemic treatment |
||
| 4 | Active infection or chronic infection requiring chronic suppressive antibiotics |
||
| 5 | Patients must not have an active infection requiring systemic therapy at time of registration |
||
| 6 | Patients must not have an active infection requiring systemic therapy |
||
| 7 | Active infection requiring treatment with antibiotics |
||
| 8 | Infection requiring systemic antibiotic therapy or other serious infection within 14 days before registration |
||
| 9 | Patients must not have a serious intercurrent illness, including ongoing or active infection requiring parental antibiotics |
||
| 10 | Patients must not have an active infection requiring systemic therapy |
||
| 11 | Active systemic infection requiring parenteral antibiotic therapy; all prior infections must have resolved following optimal therapy |
||
| 12 | Active infection (any infection requiring systemic treatment) |
||
| 13 | Patient has an infection requiring treatment with systemic antibiotics or antiviral medication or has completed treatment for such an infection within 14 days prior to planned first dose of study drug |
||
| 14 | Active infection requiring systemic antibiotic therapy. |
||
| 15 | Active infection requiring intravenous (IV) antibiotics |
||
| 16 | Has an active infection requiring systemic therapy |
||
| 17 | Active infection requiring parenteral or oral antibiotics within 2 weeks before planned start of study therapy |
||
| 18 | Has an active infection requiring systemic therapy. |
||
| 19 | Active infection requiring systemic treatment or any uncontrolled infection </= 14 days prior to enrollment |
||
| 20 | Active infection requiring systemic therapy |
||
| 21 | Active infection requiring systemic antibiotic therapy |
||
| 22 | Has an active systemic infection |
||
| 23 | Has an active infection requiring systemic therapy. |
||
| 24 | Has a known active infection requiring systemic therapy |
||
| 25 | Has an active infection requiring systemic therapy |
||
| 26 | Active infection requiring intravenous antibiotics within 1 week of study enrollment (day 1). |
||
| 27 | Active infection requiring systemic therapy |
||
| 28 | Has an active infection requiring systemic therapy |
||
| 29 | Has an active infection requiring systemic therapy |
||
| 30 | Has an active infection requiring systemic therapy |
||
| 31 | Active infection requiring intravenous antibiotics at cycle 1 day 1 |
||
| 32 | Active systemic infection requiring parenteral antibiotic therapy. All prior infections must have resolved following optimal therapy |
||
| 33 | Active infection or chronic infection requiring chronic suppressive antibiotics. |
||
| 34 | Active infection (any infection requiring systemic treatment). Hepatitis B or C [HBV/HCV] is allowed |
||
| 35 | Has an active infection requiring systemic therapy |
||
| 36 | Active infection requiring within 2 weeks prior to first dose of study drug |
||
| 37 | Has an active infection requiring systemic therapy within 3 days of registration (NOTE: except for uncomplicated urinary tract infection [UTI]) |
||
| 38 | Active infection requiring systemic antibiotic therapy. |
||
| 39 | Has an active infection requiring systemic therapy |
||
| 40 | Patient has an active infection requiring systemic therapy |
||
| 41 | Current infection requiring parenteral antibiotics |
||
| 42 | SAFETY RUN-IN: Active infection requiring systemic therapy |
||
| 43 | RANDOMIZED PHASE II CLINICAL TRIAL: Active infection requiring systemic therapy |
||
| 44 | Has an active infection requiring therapy. |
||
| 45 | Active systemic infection requiring intravenous antibiotics within 2 weeks of treatment start |
||
| 46 | Acute infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose |
||
| 47 | Has an active infection requiring systemic therapy |
||
| 48 | Active infection requiring systemic therapy |
||
| 49 | Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment |
||
| 50 | Patients who have an infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment are not eligible |
||
| 51 | Active infection requiring treatment with systemic anti-infectives or major surgery in prior 4 weeks. |
||
| 52 | Active infection requiring IV antibiotics at day 1 of cycle 1 |
||
| 53 | Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior cycle 1, day 1 |
||
| 54 | Active infection requiring systemic therapy |
||
| 55 | Active infection requiring parenteral antibiotics within 2 weeks before planned first dose of study drug |
||
| 56 | Active infection requiring IV antibiotics within 2 weeks of study dose |
||
| 57 | No active infection requiring antibiotics |
||
| 58 | Systemic infection requiring treatment with antibiotics, antifungal, or antiviral agents within seven days of registration |
||
| 59 | Serious/active infection or infection requiring parenteral antibiotics |
||
| 60 | Acute active infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose |
||
| 61 | Acute active infection requiring systemic antibiotics, antivirals, or antifungals within 14 days prior to first dose |
||
| 62 | Active infection requiring antibiotics |
||
| 63 | Has an active infection requiring systemic therapy. |
||
| 64 | Active infection requiring iv antibiotics at day 1 of cycle 1 |
||
| 65 | Active infection requiring systemic therapy. |
||
| 66 | Has an active infection requiring systemic therapy |
||
| 67 | Has an active infection requiring systemic therapy. |
||
| 68 | Subjects with active infection requiring antibiotic therapy |
||
| 69 | Active infection requiring systemic therapy. |
||
| 70 | Has an active infection requiring systemic therapy |
||
| 71 | An active infection requiring systemic therapy |
||
| 72 | Has an active infection requiring systemic therapy |
||
| 73 | Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment |
||
| 74 | Active infection (any infection requiring systemic treatment) |
||
| 75 | Active infection (infection requiring intravenous antibiotics) |
||
| 76 | Active infection requiring systemic therapy |
||
| 77 | Has an active infection requiring systemic therapy |
||
| 78 | Has an active infection requiring systemic therapy |
||
| 79 | EXCLUSION - PROCUREMENT: Active infection requiring antibiotics |
||
| 80 | Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug. Patients requiring any systemic antiviral, antifungal, or antibacterial therapy for active infection must have completed treatment no less than one week prior to the initiation of study drug |
||
| 81 | Has an active infection requiring therapy. |
||
| 82 | Active infection requiring systemic therapy |
||
| 83 | Active infection requiring systemic therapy |
||
| 84 | Active infection requiring intravenous (IV) antibiotics within 14 days before Day 1, Cycle 1 |
||
| 85 | Active infection requiring systemic antibiotic therapy |
||
| 86 | Active infection requiring intravenous antibiotics at week 1 day 1 |
||
| 87 | Has an active infection requiring systemic treatment |
||
| 88 | Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug |
||
| 89 | Active infection requiring systemic antibiotic therapy. |
||
| 90 | Must be free of systemic infection; subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection; subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment |
||
| 91 | Has an active infection requiring systemic therapy |
||
| 92 | Has an active infection requiring systemic therapy |
||
| 93 | Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug |
||
| 94 | Has an active infection requiring therapy. |
||
| 95 | Patient has an active infection requiring systemic therapy |
||
| 96 | Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment |
||
| 97 | Has an active infection requiring systemic therapy |
||
| 98 | Infection requiring intravenous antibiotic therapy or other serious infection within 14 days before study enrollment |
||
| 99 | Has an active infection requiring systemic therapy |
||
| 100 | Active infection requiring systemic antibiotic therapy |
||
| 101 | Must be free of systemic infection; subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection; subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment |
||
| 102 | Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment |
||
| 103 | Active infection requiring systemic therapy; NOTE: when the infection is controlled, patients are permitted for this study |
||
| 104 | Active infection requiring IV antibiotics on Cycle 1, Day 1 |
||
| 105 | Infection requiring intravenous (IV) antibiotic therapy or other serious infection within 14 days before randomization. |
||
| 106 | Current infection requiring parenteral antibiotics |
||
| 107 | Active infection requiring systemic antibiotic therapy. |
||
| 108 | If they have a major systemic infection requiring antibiotics 72 hours or less prior to the first dose of study drug |
||
| 109 | Has an active infection requiring systemic therapy. |
||
| 110 | EXCLUSION - PARTICIPANT: Active infection requiring systemic antibiotic therapy. Participants requiring systemic antibiotics for infection must have completed therapy before treatment is initiated. |
||
| 111 | Has an active infection requiring systemic therapy |
||
| 112 | Systemic infection requiring intravenous (IV) antibiotic or antifungal or antiviral therapy within 7 days preceding the first dose of study drug, or other severe infection |
||
| 113 | Has an active infection requiring systemic therapy |
||
| 114 | Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study drug administration |
||
| 115 | Active infection requiring systemic therapy at the time of study treatment initiation |
||
| 116 | Has an active infection requiring systemic therapy |
||
| 117 | Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis C |
||
| 118 | Known active infection requiring parenteral or oral anti-infective treatment within 14 days of initiation of therapy |
||
| 119 | Clinically significant active infection requiring intravenous antibiotics (=< 14 days prior to registration) |
||
| 120 | Has an active infection requiring systemic therapy |
||
| 121 | Has an active infection requiring systemic therapy |
||
| 122 | Must be free of systemic infection:\r\n* Subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection\r\n* Subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment |
||
| 123 | Active infection requiring systemic therapy |
||
| 124 | Active infection requiring systemic therapy. |
||
| 125 | Recent infection requiring intravenous anti-infective treatment that was completed =< 14 days before enrollment; active infection requiring systemic therapy |
||
| 126 | Serious, systemic infection requiring treatment ? 7 days before the first dose of study drug |
||
| 127 | Participants must not have an active infection requiring systemic therapy |
||
| 128 | Has an active infection requiring systemic therapy |
||
| 129 | Have a chronic or active infection that requires systemic antibiotics, antifungal or antiviral treatment |
||
| 130 | Has an active infection requiring systemic therapy |
||
| 131 | Chronic or ongoing active infectious disease requiring systemic treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis C |
||
| 132 | Current infection requiring parenteral antibiotics |
||
| 133 | Active infection requiring intravenous antibiotics (must be completed prior to registration) |
||
| 134 | Has an active infection requiring systemic therapy |
||
| 135 | Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug. Patients requiring any systemic antiviral, antifungal, or antibacterial therapy for active infection must have completed treatment no less than one week prior to the initiation of study drug. |
||
| 136 | Has an active infection requiring systemic therapy |
||
| 137 | Has an active infection requiring systemic therapy |
||
| 138 | Has an active infection at the time of cycle 1 day 1 requiring systemic therapy |
||
| 139 | Has an active infection requiring systemic therapy. |
||
| 140 | Has an active infection requiring systemic therapy. |
||
| 141 | Active infection requiring systemic therapy |
||
| 142 | Any uncontrolled infection or active infection requiring ongoing systemic treatment |
||
| 143 | Uncontrolled infection requiring systemic antibiotics/antivirals/antifungals |
||
| 144 | Active infection requiring systemic therapy |
||
| 145 | Active infection requiring systemic therapy |
||
| 146 | Currently receiving systemic antibiotic, antiviral, or antifungal therapy for the treatment of an active infection |
||
| 147 | Has an active infection requiring systemic therapy |
||
| 148 | Known infection requiring the systemic use of, for example, an antibiotic or antiviral agent |
||
| 149 | Has an active infection requiring systemic therapy |
||
| 150 | Has an active infection requiring systemic therapy |
||
| 151 | Has an active infection requiring systemic therapy. |
||
| 152 | Has an active infection requiring systemic therapy |
||
| 153 | Active infection requiring the use of systemic antibiotics |
||
| 154 | Has a clinically significant active infection requiring systemic therapy. |
||
| 155 | Participant has an active infection requiring IV antibiotics |
||
| 156 | Has an active infection requiring systemic therapy. |
||
| 157 | Has an active infection requiring systemic therapy |
||
| 158 | Has an active infection requiring systemic therapy |
||
| 159 | Active infection requiring systemic therapy |
||
| 160 | Has an active infection requiring systemic therapy. |
||
| 161 | Active infection requiring systemic antibiotics within 2 weeks prior to cycle 1, day 1; prophylactic short-term antibiotics will be allowed |
||
| 162 | Has an active infection requiring systemic therapy |
||
| 163 | Active infection requiring systemic therapy |
||
| 164 | active infection requiring systemic therapy; |
||
| 165 | Infection requiring systemic intravenous antibiotic therapy or other serious infection within 14 days before study enrollment |
||
| 166 | Has an active infection requiring systemic therapy |
||
| 167 | Has an active infection requiring systemic therapy. |
||
| 168 | Patient has active infection requiring system therapy |
||
| 169 | Active infection requiring systemic therapy |
||
| 170 | Has an active infection requiring systemic therapy |
||
| 171 | Has an active infection requiring systemic therapy |
||
| 172 | Active infection requiring systemic therapy |
||
| 173 | Active infection requiring systemic therapy |
||
| 174 | Has an active infection requiring systemic therapy |
||
| 175 | Active infection (requiring oral or intravenous antibiotics or antiviral therapy). |
||
| 176 | Has an active infection requiring systemic therapy |
||
| 177 | Has an active infection requiring systemic therapy |
||
| 178 | Has an active infection requiring systemic therapy |
||
| 179 | Has an active infection requiring systemic therapy |
||
| 180 | Other active infection requiring systemic therapy |
||
| 181 | Has an active infection requiring systemic therapy |
||
| 182 | Has an active infection requiring intravenous systemic therapy |
||
| 183 | Has an active infection requiring systemic therapy |
||
| 184 | Active infection requiring systemic therapy. |
||
| 185 | Has an active infection requiring systemic therapy |
||
| 186 | Has an active infection requiring systemic therapy |
||
| 187 | Has an active infection requiring systemic therapy |
||
| 188 | Has an active infection requiring systemic therapy |
||
| 189 | Active infection requiring intravenous antibiotics (antibiotics should have been completed prior to registration) |
||
| 190 | Has active infection requiring systemic therapy |
||
| 191 | Serious, systemic infection requiring treatment =< 7 days before the first dose of study drug |
||
| 192 | Has an active infection requiring systemic therapy |
||
| 193 | Has an active infection requiring systemic therapy (apart from cutaneous infections). |
||
| 194 | Any active infection requiring systemic treatment |
||
| 195 | Serious infection requiring parenteral antibiotic therapy or any other serious infection within 14 days before randomization. |
||
| 196 | Current active infection requiring systemic antibiotic or antifungal therapy |
||
| 197 | Has an active infection requiring systemic therapy |
||
| 198 | Has an active infection requiring systemic therapy |
||
| 199 | Has an active infection requiring systemic therapy with IV antibiotics |
||
| 200 | Active infection requiring systemic therapy |
||
| 201 | Has an active infection requiring systemic therapy |
||
| 202 | Patients active infection requiring intravenous systemic therapy |
||
| 203 | Has an active infection requiring systemic therapy |
||
| 204 | Active infection or chronic infection requiring chronic suppressive antibiotics |
||
| 205 | Has an active infection requiring systemic therapy |
||
| 206 | Active infection requiring systemic therapy. |
||
| 207 | Have active infection requiring antibiotics |
||
| 208 | Systemic infection requiring chronic maintenance or suppressive therapy |
||
| 209 | Patient has an active infection requiring systemic therapy |
||
| 210 | Has an active infection requiring systemic therapy |
||
| 211 | Has an active infection requiring systemic therapy |
||
| 212 | Active infection requiring intravenous (IV) antibiotics or other uncontrolled intercurrent illness requiring hospitalization. |
||
| 213 | Has an active infection requiring systemic therapy |
||
| 214 | Has an active infection requiring systemic therapy |
||
| 215 | Active infection, requiring systemic therapy |
||
| 216 | Has an active infection requiring systemic therapy |
||
| 217 | Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug |
||
| 218 | Active infection requiring systemic therapy |
||
| 219 | Has an active infection requiring systemic therapy |
||
| 220 | Has an active infection requiring systemic therapy |
||
| 221 | Infection requiring intravenous antibiotic use within one week of enrollment. |
||
| 222 | Has an active infection requiring systemic therapy |
||
| 223 | Has active infection requiring treatment with systemic (intravenous or oral) anti-infectives (antibiotic, antifungal, or antiviral agent) ? 10 days of C1D1 |
||
| 224 | Active infection requiring parenteral antibiotics |
||
| 225 | Has an active infection requiring systemic antibiotics within 10 days of registration |
||
| 226 | Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug |
||
| 227 | Has an active infection requiring intravenous systemic therapy |
||
| 228 | Clinically significant active infection requiring intravenous antibiotics =< 14 days prior to registration |
||
| 229 | Acute infection requiring systemic treatment |
||
| 230 | Has an active infection requiring systemic therapy |
||
| 231 | Has an active infection requiring systemic therapy |
||
| 232 | Has an active infection requiring systemic therapy |
||
| 233 | Has an active infection requiring systemic therapy |
||
| 234 | Subjects must not have a known active infection requiring intravenous antibiotic therapy |
||
| 235 | Has an active infection requiring systemic therapy |
||
| 236 | Has an active infection requiring systemic therapy |
||
| 237 | Has an active infection requiring systemic therapy. |
||
| 238 | Acute infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose |
||
| 239 | Has an active infection requiring systemic therapy; exception HIV on antiretrovirals with negative viral load |
||
| 240 | Has an active infection requiring systemic therapy |
||
| 241 | Has an active infection requiring systemic therapy |
||
| 242 | Active infection requiring systemic therapy |
||
| 243 | Has an active infection requiring intravenous systemic therapy |
||
| 244 | Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug |
||
| 245 | Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment |
||
| 246 | Has an active infection requiring systemic therapy |
||
| 247 | Has an active infection requiring systemic therapy |
||
| 248 | Has an active infection requiring systemic therapy |
||
| 249 | Ongoing infection requiring systemic treatment |
||
| 250 | Has an active infection requiring systemic therapy which is not expected to have resolved by cycle 1 day 1 dosing |
||
| 251 | Has an active infection requiring systemic therapy |
||
| 252 | Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug |
||
| 253 | Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment |
||
| 254 | Has an active infection requiring systemic therapy |
||
| 255 | Has an active infection requiring intravenous systemic therapy |
||
| 256 | Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active Hepatitis C |
||
| 257 | Has history of/active pneumonitis that required/is requiring steroid treatment or had history of/active interstitial lung disease; has an active infection requiring systemic treatment |
||
| 258 | Systemic infection requiring intravenous (IV) antibiotic therapy =< 14 days prior to registration |
||
| 259 | Has an active infection requiring systemic therapy |
||
| 260 | Has an active infection requiring systemic therapy |
||
| 261 | Current active infection requiring systemic therapy |
||
| 262 | Known HIV-1 or any active infection requiring IV antibiotics |
||
| 263 | Has an active infection requiring systemic therapy |
||
| 264 | Have an active infection requiring systemic therapy. |
||
| 265 | Serious/active infection or infection requiring parenteral antibiotics |
||
| 266 | Active infection requiring antibiotics or antifungals within 7 days prior to first dose of study drug |
||
| 267 | Has an active infection requiring systemic therapy; antimicrobial prophylaxis will be permitted at the discretion of the treating investigator |
||
| 268 | Active infection requiring treatment. |
||
| 269 | Has an active infection requiring systemic therapy |
||
| 270 | Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug |
||
| 271 | Any uncontrolled active systemic infection requiring intravenous (IV) antibiotics |
||
| 272 | Has an active infection requiring systemic therapy |
||
| 273 | Has an active infection requiring systemic therapy |
||
| 274 | Systemic infection requiring intravenous (IV) antibiotic therapy within 14 days preceding the first dose of study drug, or other severe infection |
||
| 275 | Has an active infection requiring systemic therapy |
||
| 276 | Major systemic infection requiring antibiotics 72 hours or less prior to first dose of study drug |
||
| 277 | Has an active infection requiring intravenous systemic therapy or hospital admission |
||
| 278 | Has an active infection requiring systemic therapy |
||
| 279 | Has an active infection requiring intravenous systemic therapy or hospital admission |
||
| 280 | Has an active infection requiring systemic therapy |
||
| 281 | Has an active infection requiring systemic therapy |
||
| 282 | Has active, serious infection requiring systemic therapy. Patients may receive prophylactic antibiotics and antiviral therapy at the discretion of the treating physician. |
||
| 283 | Has an active infection requiring systemic therapy |
||
| 284 | Active infection requiring intravenous (IV) antibiotic usage within the last week prior to study treatment |
||
| 285 | Has an active infection requiring systemic therapy |
||
| 286 | Active infection requiring IV antibiotics 7 days before enrollment |
||
| 287 | Has an active infection requiring systemic therapy |
||
| 288 | Active infection requiring intravenous antibiotics |
||
| 289 | Active infection requiring systemic therapy |
||
| 290 | Has an active infection requiring systemic therapy |
||
| 291 | Chronic or active hepatitis B or C infection requiring treatment with antiviral therapy |
||
| 292 | Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment |
||
| 293 | Has an active infection requiring systemic therapy |
||
| 294 | Active infection requiring parenteral antibiotics |
||
| 295 | Has an active infection requiring systemic therapy. |
||
| 296 | Active infection requiring systemic therapy |
||
| 297 | Has an active infection requiring systemic therapy |
||
| 298 | Patient has or had any active infection requiring antibiotic, antifungal, or antiviral therapy within the 2 weeks prior to administration of Toca 511. |
||
| 299 | Active infection requiring therapy |
||
| 300 | Active infection requiring systemic therapy. |
||
| 301 | Evidence of ongoing or active infection requiring intravenous antibiotics; |
||
| 302 | Has an active infection requiring intravenous antibiotic therapy |
||
| 303 | Active infection requiring intravenous antibiotics within 7 days before enrollment |
||
| 304 | Has an active infection requiring systemic therapy |
||
| 305 | Active infection requiring systemic therapy |
||
| 306 | Has an active infection requiring systemic treatment |
||
| 307 | Any other active malignancy requiring systemic therapy |
||
| 308 | Infection requiring systemic antibiotic therapy or other serious infection within 14 days prior to start of study treatment |
||
| 309 | Active infection requiring systemic therapy |
||
| 310 | Acute active infection requiring systemic therapy within 2 weeks prior to enrollment |
||
| 311 | Active infection requiring parenteral antibiotics |
||
| 312 | Has an active infection requiring systemic therapy |
||
| 313 | Active infection requiring treatment |
||
| 314 | Patients must not have an active major systemic infection requiring systemic antibiotics 72 hours or less prior to the first dose of study drug |
||
| 315 | Patients should be free of active infection requiring antibiotics |
||
| 316 | Chronic or active hepatitis B or C infection requiring treatment with antiviral therapy |
||
| 317 | Has an active infection requiring systemic therapy or hospital admission |
||
| 318 | Has an active serious bacterial infection requiring systemic therapy |
||
| 319 | Subject has an active infection requiring systemic therapy, including active tuberculosis |
||
| 320 | Active infection requiring intravenous antibiotics at the time of registration |
||
| 321 | Infection requiring systemic IV antibiotic therapy within 7 days before cycle 1 day 1 of therapy |
||
| 322 | Has an active infection requiring systemic therapy |
||
| 323 | Has an active infection requiring systemic therapy |
||
| 324 | Evidence of active infection requiring antibiotic therapy ? 14 days prior to the first dose of PRTX- 100 |
||
| 325 | Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment |
||
| 326 | Has an active infection requiring intravenous systemic therapy |
||
| 327 | Has an active infection requiring systemic therapy |
||
| 328 | Patients must be free of systemic infection requiring intravenous (IV) antibiotics at the time of registration; patients must be off IV antibiotics for at least 7 days prior to registration |
||
| 329 | Active infection requiring therapy |
||
| 330 | Active (uncontrolled) infection requiring systemic antibiotic therapy with antibacterial, antifungal, or antiviral agents (excluding HIV) |
||
| 331 | Requiring active treatment for Toxoplasma gondii infection |
||
| 332 | Uncontrolled systemic infection requiring parenteral anti-microbial therapy. |
||
| 333 | Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment |
||
| 334 | Has an active infection requiring systemic therapy |
||
| 335 | Must be free of systemic infection; subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection; subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment |
||
| 336 | Active, systemic infection requiring intravenous (IV) antibiotic, antifungal, or antiviral therapy or other serious infection within 14 days before the first dose of study drug. |
||
| 337 | Active infection requiring systemic therapy with IV antibiotics |
||
| 338 | Has an active infection requiring systemic therapy |
||
| 339 | Unstable systemic disease in the opinion of the treating physician, for example active infection requiring intravenous (IV) antibiotics |
||
| 340 | Active infection or chronic infection requiring chronic suppressive antibiotics. |
||
| 341 | Uncontrolled active infection requiring systemic antibiotics, antivirals, or antifungals within one week prior to first dose; prophylactic antimicrobials are permitted |
||
| 342 | Active infection requiring antibiotics |
||
| 343 | Systemic infection requiring intravenous (IV) antibiotic therapy within 14 days preceding the first dose of study drug, or other severe infection |
||
| 344 | Serious active infection requiring intravenous (IV) antibiotics |
||
| 345 | Active infection requiring therapy |
||
| 346 | Patient has an active infection requiring systemic therapy |
||
| 347 | Acute active infection requiring treatment should be under control |
||
| 348 | Active clinically significant infection requiring antibiotics |
||
| 349 | Must not have acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to enrollment. |
||
| 350 | Acute active infection requiring intravenous antibiotics, antiviral (except antiviral directed at hepatitis B), or antifungal agents within 14 days of first dose |
||
| 351 | Active carcinoma requiring systemic chemotherapy or radiation therapy |
||
| 352 | Patients with active infection requiring systemic antimicrobials |
||
| 353 | Active systemic infection |
||
| 354 | Patients must be free of systemic infection requiring intravenous (IV) antibiotics at the time of registration; patients must be off IV antibiotics for at least 7 days prior to registration |
||
| 355 | Acute infection requiring systemic antibiotics, antivirals, or antifungals within 14 days prior to first dose |
||
| 356 | Patients should be free of active infection requiring intravenous antibiotics |
||
| 357 | Active infection requiring antibiotics |
||
| 358 | Chronic or current active infection requiring systemic antibiotic, antifungal, or antiviral treatment |
||
| 359 | Active infection requiring systemic therapy. |
||
| 360 | Active infection requiring systemic antibiotic therapy. Patients requiring systemic antibiotics for infection must have completed therapy before Screening is initiated |
||
| 361 | Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug |
||
| 362 | Recent infection requiring systemic treatment that was completed |
||
| 363 | Patients with an active infection that require systemic antibiotics, antiviral, or antifungal treatments |
||
| 364 | Presence of a fungal infection requiring systemic antifungal treatment at enrollment |
||
| 365 | Patients must be free of systemic infection requiring intravenous (IV) antibiotics at the time of registration; patients must be off IV antibiotics for at least 7 days prior to registration |
||
| 366 | Active infection requiring treatment with systemic antibiotics or systemic anti-fungal agents |
||
| 367 | Active infection requiring parenteral antibiotics |
||
| 368 | Active infection requiring oral or intravenous antibiotics |
||
| 369 | An active infection requiring systemic IV therapy. |
||
| 370 | Subject has active infection requiring systemic therapy that has not completely resolved within 14 days prior to start of study treatment. |
||
| 371 | Has an active infection requiring systemic therapy |
||
| 372 | Active infection requiring systemic therapy |
||
| 373 | Has an active infection requiring systemic therapy NOTE: Antibiotic therapy must have been completed a minimum of 3 days prior to start of study treatment; |
||
| 374 | Has an active infection requiring systemic therapy |
||
| 375 | Active systemic infection requiring parenteral antibiotic therapy |
||
| 376 | Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment. |
||
| 377 | Active infection or chronic infection requiring chronic suppressive antibiotics. |
||
| 378 | Has an active infection requiring systemic therapy. |
||
| 379 | Has an active infection requiring systemic therapy |
||
| 380 | Patients with any serious active infection (i.e., requiring an intravenous antibiotic, antifungal, or antiviral agent) |
||
| 381 | Patients who have an acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to registration are NOT eligible for participation |
||
| 382 | Patient has an active systemic infection requiring treatment or within 14 days before first dose of PRLX 93936. |
||
| 383 | Infection requiring intravenous antibiotic use within 1 week. |
||
| 384 | Serious, concomitant disorder, including active systemic infection requiring treatment, in the opinion of the investigator; |
||
| 385 | Active infection requiring systemic therapy; |
||
| 386 | Active infection requiring antibiotic, antiviral, or antifungal treatment. |
||
| 387 | Active infection requiring systemic therapy. |
||
| 388 | Active clinically serious infection requiring intravenous antibiotics at the time of study entry (CTCAE Grade 2) |
||
| 389 | If they have a major systemic infection requiring antibiotics 72 hours or less prior to the first dose of study drug |
||
| 390 | Active infection requiring treatment. |
||
| 391 | Active infection requiring systemic therapy |
||
| 392 | Active infection requiring systemic therapy. |
||
| 393 | Evidence of active tuberculosis or recent clinically-significant infection requiring systemic therapy. |
||
| 394 | Has an active infection requiring systemic therapy |
||
| 395 | Active infection requiring systemic therapy. |
||
| 396 | Major active infection requiring parenteral antibiotics. |
||
| 397 | Infection requiring systemic antibiotic therapy within 14 days prior to the start of study treatment |
||
| 398 | Active infection requiring IV antibiotic usage within the last week prior to study treatment |
||
| 399 | Has an active infection requiring systemic therapy |
||
| 400 | Infection requiring intravenous antibiotic use within 1 week. |
||
| 401 | Active infection, chronic or severe infection requiring ongoing antimicrobial therapy. |
||
| 402 | REGISTRATION TO TREATMENT (STEP 1): Patient must not have an active infection requiring systemic therapy |
||
| 403 | REGISTRATION TO TREATMENT (STEP 2): Patient must not have an active infection requiring systemic therapy |
||
| 404 | Active infection requiring parenteral antibiotics |
||
| 405 | Active infection requiring intravenous (IV) antibiotics or other uncontrolled intercurrent illness requiring hospitalization. |
||
| 406 | Active infection requiring intravenous (IV) antibiotics or other uncontrolled intercurrent illness requiring hospitalization |
||
| 407 | Infection requiring systemic antibiotic therapy or other serious infection ? 7 days prior to registration |
||
| 408 | Has an active infection requiring systemic therapy |
||
| 409 | Has an active infection requiring systemic therapy; prior to dosing with REGN2810 the subject must be at least 5 half-lives from their last dose of antibiotic |
||
| 410 | Has an active infection requiring systemic therapy. |
||
| 411 | Active infection requiring systemic therapy |
||
| 412 | Patient has an active infection requiring systemic therapy |
||
| 413 | Has an active infection requiring systemic therapy |
||
| 414 | Has an active infection requiring systemic therapy |
||
| 415 | Acute infection requiring systemic treatment |
||
| 416 | Recent culture-documented infection requiring systemic intravenous treatment that was completed =< 7 days before the first dose of study drug or any uncontrolled active systemic infection; fever of unknown origin is not an exclusion criterion, as this may be disease-related |
||
| 417 | Has an active viral infection requiring systemic therapy |
||
| 418 | Has an active infection requiring systemic therapy |
||
| 419 | Ongoing or active infection requiring systemic treatment (must be afebrile for >= 48 hours prior to study registration) |
||
| 420 | Active infection requiring parenteral antibiotics. |
||
| 421 | Active systemic infection requiring treatment, including any human immunodeficiency virus (HIV) infection or toxoplasmosis |
||
| 422 | Has an active infection requiring systemic therapy |
||
| 423 | Has an active infection requiring systemic therapy with the exception of an uncomplicated urinary tract infection |
||
| 424 | Evidence of ongoing or active infection requiring antibiotic therapy |
||
| 425 | Active infection requiring systemic therapy |
||
| 426 | Has an active infection requiring systemic therapy |
||
| 427 | Serious infection requiring treatment with intravenous antibiotics at the time of study entrance, or an infection requiring intravenous therapy within 7 days prior. |
||
| 428 | Active infection requiring systemic antibiotic therapy. |
||
| 429 | Serious infection requiring hospitalization or intravenous (IV) antibiotics within 14 days prior to enrollment |
||
| 430 | Subjects with active infection requiring IV antibiotics within 2 weeks of study enrollment (day 1) are excluded |
||
| 431 | Active or chronic infection requiring systemic therapy |
||
| 432 | Has an active infection requiring systemic therapy |
||
| 433 | Active infection requiring treatment or chronic infection requiring suppressive therapy |
||
| 434 | Chronic or active hepatitis B or C infection requiring treatment with antiviral therapy |
||
| 435 | Active infection requiring systemic treatment within one week prior to first dose. |
||
| 436 | Active infection requiring systemic therapy |
||
| 437 | Active infection requiring treatment at the time of study treatment initiation |
||
| 438 | Participants with an active infection requiring systemic therapy |
||
| 439 | Has an active infection requiring systemic therapy |
||
| 440 | Has an active infection requiring systemic therapy |
||
| 441 | Has an active infection requiring systemic therapy |
||
| 442 | Has an active infection requiring systemic therapy |
||
| 443 | Active infection requiring systemic antibiotic therapy with antibacterial, antifungal, or antiviral agents (excluding HIV) |
||
| 444 | Requiring active treatment for Toxoplasma gondii |
||
| 445 | Participants with an active infection requiring antibiotics are excluded (a positive screening urinalysis may be repeated) |
||
| 446 | Has an active infection requiring systemic therapy |
||
| 447 | Has an active infection requiring systemic therapy |
||
| 448 | Has an active infection requiring systemic therapy |
||
| 449 | Patients must not have an active infection requiring current treatment with parenteral antibiotics |
||
| 450 | Active infection requiring systemic therapy |
||
| 451 | Has an active infection requiring systemic therapy |
||
| 452 | Has an active infection requiring systemic therapy or history of repeated infections |
||
| 453 | Active infection requiring antibiotics or antifungals within 7 days prior to first dose of study drug |
||
| 454 | Systemic infection requiring chronic maintenance or suppressive therapy |
||
| 455 | Uncontrolled infection requiring active treatment (systemic antibiotics, anti-virals, or anti-fungals) within 14 days |
||
| 456 | Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment unless the patient is felt to have fully recovered and any antibiotics that are continued are either beta lactam antibiotics or are specifically allowed on study |
||
| 457 | Active infection or chronic infection requiring chronic suppressive antibiotics |
||
| 458 | Active infection requiring intravenous antibiotics |
||
| 459 | Patients with active infection requiring systemic antimicrobials |
||
| 460 | Active infection requiring systemic therapy |
||
| 461 | Has an active infection requiring systemic treatment |
||
| 462 | Has an active infection requiring systemic therapy. |
||
| 463 | Active infection requiring intravenous systemic therapy. |
||
| 464 | Active infection requiring systemic therapy |
||
| 465 | Any active infection requiring antibiotic therapy within 2 weeks of study day 1. |
||
| 466 | Has an active infection requiring systemic therapy. |
||
| 467 | Has an active infection requiring systemic therapy |
||
| 468 | Evidence of active tuberculosis or recent (<1 week prior to first scheduled dosing) clinically significant infection requiring systemic therapy. |
||
| 469 | Patients must not have an active infection requiring systemic therapy |
||
| 470 | Active infection requiring systemic therapy. |
||
| 471 | Has an active infection requiring systemic therapy. |
||
| 472 | Evidence of any active infection requiring hospitalization or IV antibiotics within 2 weeks prior to study enrolment. |
||
| 473 | Active infection requiring systemic therapy. |
||
| 474 | Has an active infection requiring therapy. |
||
| 475 | Active infection requiring treatment ? 7 days before first dose of study drug |
||
| 476 | Has an active infection or recent history (<30 days before study drug administration) requiring systemic treatment |
||
| 477 | Has an active infection requiring systemic therapy. |
||
| 478 | Active infection requiring systemic therapy |
||
| 479 | Presence of active infection requiring systemic therapy |
||
| 480 | Subject has active infection requiring systemic therapy |
||
| 481 | Active infection requiring systemic therapy at enrollment |
||
| 482 | Has an active infection requiring systemic treatment |
||
| 483 | Active systemic infection requiring treatment. Infection controlled by oral therapy will not be exclusionary. |
||
| 484 | Has an active infection requiring systemic therapy or uncontrolled infection. |
||
| 485 | Active systemic infection requiring treatment. Infection controlled by oral therapy will not be exclusionary. |
||
| 486 | Active infection, or chronic infection requiring chronic suppressive antibiotics. |
||
| 487 | No active systemic infection requiring parenteral antibiotic therapy |
||
| 488 | Patients should be free of active infection requiring parenteral antibiotics. |
||
| 489 | Patients with active infection requiring parenteral antibiotics. |
||
| 490 | Active infection requiring therapy |
||
| 491 | Systemic infection requiring IV antibiotic therapy within 7 days preceding the first dose of study drug, or other severe infection |
||
| 492 | Has an active infection requiring systemic therapy |
||
| 493 | Active infection (any infection requiring treatment). |
||
| 494 | Has an active infection requiring systemic therapy |
||
| 495 | Patients with active infection and requiring intravenous (IV) or oral antibiotics |
||
| 496 | No active infection requiring systemic therapy |
||
| 497 | Serious active infection requiring intravenous (i.v.) antibiotics at enrollment |
||
| 498 | Has an active infection requiring systemic therapy |
||
| 499 | Recent infection requiring systemic treatment that was completed =< 14 days before starting treatment on the study |
||
| 500 | Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug |
||
| 501 | Has an active infection requiring systemic therapy |
||
| 502 | Any known HIV infection or AIDS or any concurrent infection requiring IV antibiotics |
||
| 503 | Has an active infection requiring systemic therapy |
||
| 504 | Systemic infection requiring intravenous (IV) antibiotic therapy within 14 days preceding the first dose of study drug, or other severe infection |
||
| 505 | Has an active infection requiring systemic therapy |
||
| 506 | Active infection requiring IV systemic therapy |
||
| 507 | Active infection requiring systemic therapy within 14 days |
||
| 508 | Active infection requiring systemic therapy |
||
| 509 | Infection requiring systemic antibiotic therapy or other serious infection within 14 days before first dose of study drug |
||
| 510 | Patients must not have uncontrolled active systemic infection requiring intravenous antibiotics |
||
| 511 | Patients with active systemic infection requiring intravenous antibiotics |
||
| 512 | Serious infection requiring systemic antibiotic therapy within 14 days prior to study treatment. |
||
| 513 | Participant has an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy |
||
| 514 | Active infection requiring systemic therapy. |
||
| 515 | Uncontrolled active systemic infection or recent infection requiring parenteral anti-microbial therapy |
||
| 516 | Active infection requiring systemic antibiotic therapy. |
||
| 517 | Active infection requiring systemic therapy |
||
| 518 | Active infection requiring parenteral antibiotics, antivirals, or antifungals within 2 weeks prior to first dose of study drug |
||
| 519 | Has an active infection requiring systemic therapy |
||
| 520 | Active infection requiring systemic antibiotic therapy. Patients requiring systemic antibiotics for infection must have completed therapy before Screening |
||
| 521 | Serious active infection requiring intravenous antibiotics and/or hospitalization at study entry |
||
| 522 | Has an active infection requiring systemic therapy |
||
| 523 | Current infection requiring parenteral antibiotics |
||
| 524 | Active infection requiring systemic therapy |
||
| 525 | Patients with active infection requiring systemic antibiotics, antiviral, or antifungal treatments |
||
| 526 | Has an active infection requiring systemic therapy |
||
| 527 | Ongoing or active infection requiring systemic treatment |
||
| 528 | Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment |
||
| 529 | Has an active infection requiring systemic therapy |
||
| 530 | Has an active infection requiring systemic therapy |
||
| 531 | Active infection requiring systemic therapy |
||
| 532 | Participant has an active infection requiring therapy. |
||
| 533 | Has an active infection requiring systemic antibiotics within 7 days of registration |
||
| 534 | Has an active infection requiring systemic therapy |
||
| 535 | Active infection requiring systemic therapy. |
||
| 536 | Has an active infection requiring systemic therapy |
||
| 537 | Clinically relevant active infection requiring treatment (antibiotics, antivirals, antifungals) |
||
| 538 | Has an active infection requiring systemic therapy |
||
| 539 | Has an active infection requiring systemic therapy |
||
| 540 | Acute infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to initiation of study |
||
| 541 | Active infection within the 14 days prior to randomization requiring systemic antibiotics |
||
| 542 | Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment |
||
| 543 | Has an active infection requiring systemic therapy |
||
| 544 | Any infection requiring ongoing intravenous antibiotics for management |
||
| 545 | Has an active infection requiring systemic therapy (? grade 2) for more than 3 days within 1 week of enrollment. |
||
| 546 | Active infection requiring systemic therapy |
||
| 547 | Active infection requiring therapy |
||
| 548 | Has an active infection requiring systemic therapy |
||
| 549 | Active infection requiring systemic therapy |
||
| 550 | Any infection requiring antibiotic or anti-viral treatment within 4 weeks of screening |
||
| 551 | Has an active infection requiring systemic therapy |
||
| 552 | Has an active infection requiring systemic therapy |
||
| 553 | Active infection requiring systemic therapy |
||
| 554 | Patient has evidence of a serious active infection (e.g., infection requiring treatment with intravenous antibiotics). |
||
| 555 | Has an active infection requiring systemic therapy |
||
| 556 | Has an active infection requiring systemic therapy |
||
| 557 | Has an active infection requiring systemic therapy |
||
| 558 | Active infection requiring intravenous (IV) antibiotics or other uncontrolled intercurrent illness requiring hospitalization |
||
| 559 | Active infection requiring treatment |
||
| 560 | Active infection requiring antibiotics or antifungals within 7 days prior to first dose of study drug |
||
| 561 | Acute infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to initiation of study |
||
| 562 | Has an active infection requiring systemic therapy |
||
| 563 | Active infection requiring systemic therapy |
||
| 564 | Systemic infection requiring IV antibiotic therapy within 7 days preceding the first dose of study drug, or other severe infection |
||
| 565 | Active infection requiring systemic therapy |
||
| 566 | Active infection requiring systemic therapy |
||
| 567 | Systemic infection requiring intravenous (IV) antibiotic therapy within 14 days preceding the first dose of study drug, or other severe infection |
||
| 568 | Infection requiring intravenous (IV) antibiotic therapy or other serious infection within 14 days before randomization. |
||
| 569 | Active infection requiring treatment ?7 days before the first dose of study drug |
||
| 570 | Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis C |
||
| 571 | Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment |
||
| 572 | Serious infection requiring treatment with systemically administered antibiotics at the time of study entrance, or an infection requiring systemic antibiotic therapy within 7 days prior to the first dose of study treatment. |
||
| 573 | Active infection requiring systemic therapy |
||
| 574 | Presence of an acute infection requiring active treatment with antibiotics/antivirals; prophylactic administration is allowed |
||
| 575 | Serious infection requiring treatment with intravenous antibiotics at the time of study entrance, or an infection requiring intravenous therapy within 7 days prior to the first dose of study treatment. |
||
| 576 | No acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to cycle 1 day 1 |
||
| 577 | Active infection requiring systemic therapy |
||
| 578 | Active infection requiring treatment within two weeks prior to first dose. |
||
| 579 | Active infection requiring treatment with IV antibiotics or hospitalized for treatment of an active infection in 4 wks prior to starting dose of AMG 592. |
||
| 580 | Has any active infection requiring systemic therapy |
||
| 581 | Active infection requiring systemic therapy. |
||
| 582 | Patients with active infection and requiring intravenous (IV) or oral antibiotics |
||
| 583 | Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to signing consent |
||
| 584 | Active infection at initiation of study; recent infections requiring systemic treatment need to have completed therapy > 14 days before the first dose of study drug |
||
| 585 | Serious/active infection or infection requiring parenteral antibiotics |
||
| 586 | Active infection requiring systemic antibiotics, antivirals, or antifungals within 2 weeks prior to first dose |
||
| 587 | Active infection (any infection requiring treatment). |
||
| 588 | Active infection requiring systemic antibiotic therapy |
||
| 589 | Infection requiring intravenous antibiotics within 14 days before the first dose of study drug |
||
| 590 | Acute active infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose |
||
| 591 | Presence of acute active infection requiring antibiotics |
||
| 592 | Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment |
||
| 593 | Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis C |
||
| 594 | Must be free of systemic infection; subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection; subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment |
||
| 595 | Serious active infection requiring i.v. antibiotics and/or hospitalization at study entry |
||
| 596 | Presence of an active systemic infection requiring treatment. |
||
| 597 | Infection requiring systemic antibiotic therapy or other serious infection within 14 days before randomization. |
||
| 598 | Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis C |
||
| 599 | Patients with an active infection requiring antibiotics |
||
| 600 | Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment as such, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis C |
||
| 601 | Patients should be free of active infection requiring antibiotics |
||
| 602 | Has an active infection requiring systemic therapy |
||
| 603 | Patients with active infection requiring intravenous (IV) antibiotics within 2 weeks of registration |
||
| 604 | Active infection requiring systemic therapy |
||
| 605 | Has an active infection requiring systemic therapy |
||
| 606 | Has an active infection requiring systemic therapy. |
||
| 607 | Evidence of active viral, bacterial, or systemic fungal infection requiring systemic treatment within 7 days prior to the first dose of study drug. Patients requiring any systemic antiviral, antifungal, or antibacterial therapy for active infection must have completed treatment no less than 7 days prior to the first dose of study drug. |
||
| 608 | Has an active infection requiring systemic therapy |
||
| 609 | Any uncontrolled active systemic infection or recent infection requiring intravenous anti-infective treatment that was completed =< 14 days before the first dose of study drug |
||
| 610 | Has an active infection requiring systemic therapy |
||
| 611 | Active infection requiring systemic therapy; |
||
| 612 | Active infection (any infection requiring systemic treatment) |
||
| 613 | Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment |
||
| 614 | Patients must not have a serious intercurrent illness including, but not limited to, ongoing or active infection requiring parenteral antibiotics |
||
| 615 | Active systemic infection |
||
| 616 | Subject has evidence of an active infection requiring systemic therapy within 14 days prior to the planned first dose of study drug. |
||
| 617 | Has an active infection requiring systemic therapy |
||
| 618 | Has an active infection requiring systemic therapy |
||
| 619 | Has an active infection requiring therapy |
||
| 620 | Evidence of active infection requiring systemic therapy |
||
| 621 | Have an active infection requiring systemic therapy |
||
| 622 | Systemic infection requiring IV antibiotic therapy within 14 days preceding the first dose of study drug, or other severe infection |
||
| 623 | Current severe, uncontrolled systemic disease including an ongoing, active infection requiring treatment with antibiotics |
||
| 624 | Patients with an active infection that requires systemic antibiotics, antiviral, or antifungal treatments |
||
| 625 | Subject has evidence of active infection requiring systemic therapy within 14 days prior to the first dose of study drug. |
||
| 626 | Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment |
||
| 627 | Concurrent serious infection requiring parenteral antibiotic therapy. |
||
| 628 | Active systemic infection |
||
| 629 | Active clinically significant infection requiring antibiotics |
||
| 630 | Known active systemic infection (Grade ?2). |
||
| 631 | Recent infection requiring intravenous (IV) systemic treatment that was completed ?14 days before the first dose of study drug. |
||
| 632 | Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment |
||
| 633 | Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment |
||
| 634 | Presence of uncontrolled infection requiring systemic therapy |
||
| 635 | Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to enrollment |
||
| 636 | Has an active infection requiring antibiotics |
||
| 637 | Ongoing or active infection requiring parental antibiotics on Day 1 |
||
| 638 | Known active infection requiring antibiotics within 7 days of the start of treatment (day 0) |
||
| 639 | Has an active infection requiring systemic therapy |
||
| 640 | Active infection requiring systemic therapy. |
||
| 641 | Has an active infection requiring systemic therapy. |
||
| 642 | Has an active infection requiring systemic therapy. |
||
| 643 | Known active infection requiring antibiotic treatment before the start of treatment (day 0) |
||
| 644 | Ongoing or active infection requiring parenteral antibiotics. |
||
| 645 | Ongoing or active infection requiring IV antibiotics |
||
| 646 | Active infection requiring antibiotics |
||
| 647 | Has an active infection requiring systemic therapy |
||
| 648 | Subject has systemic infection requiring intravenous (IV) antibiotic therapy within 7 days preceding the first dose of study drug, or other severe infection |
||
| 649 | Active infection requiring intravenous antibiotics |
||
| 650 | Has an active infection requiring systemic antibiotics. |
||
| 651 | Active infection requiring antibiotics |
||
| 652 | Active infection requiring intravenous (IV) antibiotics |
||
| 653 | Patient with an infection requiring treatment with systemic antibiotics or antiviral medication or has completed treatment for such an infection within 4 days prior to planned initial dose of WT2725. |
||
| 654 | Serious infection requiring intravenous antibiotic therapy within 14 days prior to study treatment |
||
| 655 | Active systemic infection requiring systemic antibiotic treatment within 72 hours prior to first dose of study treatment |
||
| 656 | Active systemic hepatitis infection requiring treatment or other clinically active liver disease |
||
| 657 | evidence of active infection requiring systemic therapy. |
||
| 658 | Ongoing or active infection requiring antibiotics; |
||
| 659 | Serious, uncontrolled infection requiring systemic antibiotic, antifungal or antiviral therapy |
||
| 660 | Active infection requiring systemic antibacterial/antibiotic, antifungal, or antiviral therapy. |
||
| 661 | Has an active infection requiring systemic antibiotics |
||
| 662 | Active infection requiring IV antibiotics |
||
| 663 | Serious infection requiring treatment with systemically administered antibiotics at the time of study entrance, or an infection requiring systemic antibiotic therapy within 7 days prior to the first dose of study treatment. |
||
| 664 | Acute active infection requiring treatment. |
||
| 665 | Active infection requiring intravenous antibiotics. |
||
| 666 | Active infection requiring antibiotics |
||
| 667 | Serious/active infection or infection requiring parenteral antibiotics |
||
| 668 | Acute active infection requiring treatment. |
||
| 669 | Active infection requiring parenteral antibiotics |
||
| 670 | Current acute infection requiring intravenous antibiotics |
||
| 671 | Active infection requiring antibiotics |
||
| 672 | Serious infection requiring treatment with systemically administered antibiotics at the time of study entrance, or an infection requiring systemic antibiotic therapy within 7 days prior to the first dose of study treatment. |
||
| 673 | Acute active infection requiring systemic antibiotics, antiviral (except antiviral directed at hepatitis B) or antifungal agents within 14 days of first dose |
||
| 674 | The patient has ongoing or active infection requiring parenteral antibiotics. |
||
| 675 | Active infection requiring antibiotics |
||
| 676 | Serious infection requiring parenteral antibiotics within 14 days of enrollment |
||
| 677 | Infection requiring IV antibiotic therapy or other serious infection within 14 days prior to first dose of study drug |
||
| 678 | Systemic infection requiring IV antibiotic therapy within 14 days preceding the first dose of study drug, or other severe infection |
||
| 679 | Acute active infection requiring systemic antibiotics, antivirals, or antifungals within 14 days prior to first dose |
||
| 680 | Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to randomization |
||
| 681 | Active infection requiring IV antibiotics within 2 weeks prior to screening |
||
| 682 | Active infection requiring intravenous (IV) antibiotics |
||
| 683 | Active infection requiring treatment with systemic (intravenous or oral) anti-infectives (antibiotic, antifungal, or antiviral agent) within 72 hours of screening. |
||
| 684 | Serious infection requiring treatment with systemically administered antibiotics at the time of study entrance, or an infection requiring systemic antibiotic therapy within 7 days prior to the first dose of study treatment. For the HCC, HCC/BTC and BTC subgroups hepatitis C infection and hepatitis B infection if controlled with antiviral therapy are allowable. |
||
| 685 | Acute active infection requiring systemic antibiotics, antivirals, or antifungals within 14 days prior to first dose |
||
| 686 | Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis C |
||
| 687 | Active infection requiring systemic anti-microbial treatment (including antibiotics, anti-fungals, and anti-viral agents) |
||
| 688 | Active infection requiring therapy |
||
| 689 | Active infection requiring iv antibiotics |
||
| 690 | Acute active infection requiring systemic antibiotics, antiviral (except antiviral therapy directed at hepatitis B) or antifungal agents within 14 days prior to randomization. |
||
| 691 | Serious/active infection or infection requiring parenteral antibiotics |
||
| 692 | Patient has an active systemic infection requiring treatment. |
||
| 693 | Active, serious infection requiring systemic therapy |
||
| 694 | Patients with active infection requiring systemic antibiotics, antiviral, or antifungal treatments |
||
| 695 | History of any infection requiring hospitalization or intravenous antibiotics within 2 weeks before enrollment. |
||
| 696 | Active infection requiring (IV) antibiotics within 2 weeks of study enrollment |
||
| 697 | Has an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy |
||
| 698 | The participant has an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy. |
||
| 699 | Active infection requiring IV antibiotics |
||
| 700 | Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to randomization |
||
| 701 | Patients with active infection requiring systemic treatment |
||
| 702 | Active infection requiring parenteral antibiotics within one-week prior to study |
||
| 703 | Active infection requiring antibiotic treatment |
||
| 704 | Active infection requiring antibiotic therapy |
||
| 705 | Active HSV infection requiring treatment, or requiring intermittent or chronic systemic (intravenous or oral) treatment with an antiherpetic drug (e.g. acyclovir) |
||
| 706 | Active infection requiring parenteral antibiotics |
||
| 707 | Has an active infection requiring systemic therapy |
||
| 708 | Systemic infection requiring intravenous (IV) antibiotic therapy within 14 days preceding the first dose of study drug, or other severe infection |
||
| 709 | Evidence of active infection requiring systemic therapy |
||
| 710 | Any infection requiring antibiotics within the past 2 weeks. |
||
| 711 | Has an active infection requiring intravenous systemic therapy |
||
| 712 | Have an active, clinically significant serious infection requiring intravenous treatment with antibiotics, antivirals, or antifungals. |
||
| 713 | Has active infection requiring systemic therapy |
||
| 714 | Serious infection requiring antibiotics |
||
| 715 | Patients must not have an active infection requiring systemic therapy nor a viral infection requiring intermittent treatment with an antiherpetic drug, other than intermittent topical use |
||
| 716 | Systemic infection requiring IV antibiotic therapy or other serious infection within 14 days before the first dose of study drug. |
||
| 717 | Active infection requiring systemic therapy |
||
| 718 | Has an active infection requiring systemic therapy |
||
| 719 | Local or systemic infection |
||
| 720 | Active systemic infection |
||
| 721 | Recent infection requiring intravenous systemic treatment that was completed =< 14 days before the first dose of study drug or any uncontrolled active systemic infection |
||
| 722 | Recent infection requiring systemic treatment that was completed =< 7 days before the first dose of study drug |
||
| 723 | Has an active infection requiring systemic therapy |
||
| 724 | Serious concomitant medical condition that could interfere with the conduct of the clinical trial, such as unstable angina, renal failure requiring hemodialysis, or active infection requiring intravenous (IV) antibiotics |
||
| 725 | Any infection requiring parenteral antibiotics within the past 2 weeks |
||
| 726 | Active infection requiring IV anti-infective therapy |
||
| 727 | Diagnosis of an infection requiring intravenous (IV) antibiotics 14 days prior to registration |
||
| 728 | Active infection requiring antibiotics |
||
| 729 | Active infection requiring systemic therapy |
||
| 730 | A serious, concomitant disorder, including active systemic infection requiring treatment |
||
| 731 | Active infection requiring within 2 weeks prior to first dose of study drug |
||
| 732 | Known active infection requiring antibiotic treatment |
||
| 733 | Have a chronic or active infection that requires systemic antibiotics, antifungal or antiviral treatment |
||
| 734 | acute systemic infection and |
||
| 735 | No active infection within 14 days of study enrollment requiring parenteral antibiotics |
||
| 736 | Infection requiring systemic antibiotic therapy within 14 days prior to start of study treatment |
||
| 737 | Patients should be free of active infection requiring antibiotics |
||
| 738 | Has an active infection requiring systemic therapy |
||
| 739 | A non?urologic bacterial infection requiring active treatment with antibiotics |
||
| 740 | Active infection requiring systemic IV antibiotic therapy |
||
| 741 | Has an active infection requiring systemic therapy. |
||
| 742 | Active infection requiring systemic therapy |
||
| 743 | Current active infection requiring systemic treatment. |
||
| 744 | Active infection requiring systemic therapy |
||
| 745 | Has an active infection requiring systemic therapy |
||
| 746 | Active infection requiring systemic therapy |
||
| 747 | Has an active infection requiring systemic treatment |
||
| 748 | Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment |
||
| 749 | Active infection requiring oral or intravenous antibiotics |
||
| 750 | have an active infection requiring antibiotic therapy, or concomitant malignancies |
||
| 751 | The participant has an active infection (requiring intravenous [IV] antibiotics), including tuberculosis. |
||
| 752 | The participant has an active infection (requiring I.V antibiotics), including tuberculosis. |
||
| 753 | Known active infection requiring antibiotics within 7 days of initiation of study treatment, unless considered controlled in the opinion of the investigator |
||
| 754 | Has an active infection requiring systemic therapy |
||
| 755 | Systemic infection requiring intravenous antibiotic therapy or other serious infection within 14 days before the first dose of study drug. |
||
| 756 | Has an active infection requiring systemic therapy. |
||
| 757 | Active infection (any infection requiring treatment). |
||
| 758 | Has an active infection requiring systemic therapy |
||
| 759 | Has an active infection requiring intravenous systemic therapy. |
||
| 760 | Has an active infection requiring systemic therapy |
||
| 761 | Has an active infection requiring systemic therapy |
||
| 762 | Current infection requiring parenteral antibiotics |
||
| 763 | Has an active infection requiring systemic therapy |